Ceribell makes the Ceribell System, a portable EEG brain monitoring platform that hospitals use to detect seizures in acute care patients. CBLL reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 2 | TD Cowen | Maintained | Buy | |
| Aug 11 | Canaccord Genuity | Maintained | Buy | |
| Aug 11 | BTIG | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in CBLL in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBLL is in one of them and how their past CBLL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CBLL in an article yet. Here's the latest on the wider market.
About Ceribell
Ceribell is a medical technology company based in Sunnyvale, California. It makes the Ceribell System, a portable brain monitoring platform used to detect and track seizures in patients in acute care settings. The system includes disposable headbands and a small recorder that send brain activity data to a web portal, where neurologists can view it in real time. Artificial intelligence algorithms help flag seizure activity. Its customers are hospitals, where nurses, technicians and neurologists use the system.
- Headquarters
- Sunnyvale, CA